Revvity, Inc. (NYSE: RVTY), announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status ...

Researchers from the Odense University Hospital in Denmark evaluated the performance of 6 commercially available SARS-CoV-2 antibody detection assays, two of which utilized ELISA (11). Both EUROIMMUN ...

Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support ...

WALTHAM, Mass., March 03, 2025--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a ...

Revvity, Inc. , today announced the launch of EUROIMMUN's CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a measles virus infection or to determine the immune status against ...

The enzyme-linked immunosorbent assay (ELISA) is a sensitive method to quantify or test for the presence of antigen or ligand. Enzyme-linked antibodies (or ligand binding proteins) are used to ...

NEW YORK – Revvity's Euroimmun subsidiary is expanding its fungal disease testing menu with molecular tests to aid the detection of a broader range of pathogens and genetic markers of drug resistances ...

Market Open. WALTHAM, Mass., March 03, 2025--Revvity, Inc. (NYSE: RVTY), today announced the launch of EUROIMMUN’s CE-marked Anti-Measles Virus ELISA 2.0 (IgG) to support the diagnosis of a ...

Sera were collected 40-45 days after the second dose and anti-SARS-CoV-2 antibody concentrations were measured using the Euroimmun Anti-SARS CoV-2 ELISA IgG kit (Euroimmun, Luebeck, Germany). Briefly, ...